Find Difelikefalin manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Canada

Canada

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1024828-77-0, Cr845, Difelikefalin [inn], Mr13a9, Cr-845, Korsuva
Molecular Formula
C36H53N7O6
Molecular Weight
679.8  g/mol
InChI Key
FWMNVWWHGCHHJJ-SKKKGAJSSA-N
FDA UNII
NA1U919MRO

Difelikefalin
Difelikefalin (CR845) is an agonist of kappa opioid receptors (KORs) useful in the treatment of pruritus secondary to chronic kidney disease. KORs were first associated with itching in 1984. Further investigations revealed that dynorphins, endogenous agonists of KORs, work to inhibit the itching sensation at the spinal cord level, and scratching could be elicited in mouse models with the administration of KOR antagonists. These revelations led to the study of KOR agonists as a potential treatment option in patients suffering from pruritic conditions. Pruritus associated with chronic kidney disease (also called uremic pruritus) affects 50-60% of all patients on dialysis and 25% of non-dialysis patients with chronic kidney disease. The clinical burden of uremic pruritus in this patient population is being increasingly recognized as contributing to a significant reduction in patient quality of life, poor outcomes, and even mortality. Options for therapy are limited - with no FDA-approved treatments, off-label [gabapentin] was the most evidence-based and widely available treatment. Difelikefalin received FDA approval in August 2021 (under the brand name Korsuva), becoming the first FDA-approved therapy for patients with chronic kidney disease suffering from uremic pruritus.
1 2D Structure

Difelikefalin

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-amino-1-[(2R)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid
2.1.2 InChI
InChI=1S/C36H53N7O6/c1-24(2)21-29(32(45)40-28(15-9-10-18-37)34(47)43-19-16-36(39,17-20-43)35(48)49)42-33(46)30(23-26-13-7-4-8-14-26)41-31(44)27(38)22-25-11-5-3-6-12-25/h3-8,11-14,24,27-30H,9-10,15-23,37-39H2,1-2H3,(H,40,45)(H,41,44)(H,42,46)(H,48,49)/t27-,28-,29-,30-/m1/s1
2.1.3 InChI Key
FWMNVWWHGCHHJJ-SKKKGAJSSA-N
2.1.4 Canonical SMILES
CC(C)CC(C(=O)NC(CCCCN)C(=O)N1CCC(CC1)(C(=O)O)N)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC3=CC=CC=C3)N
2.1.5 Isomeric SMILES
CC(C)C[C@H](C(=O)N[C@H](CCCCN)C(=O)N1CCC(CC1)(C(=O)O)N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CC3=CC=CC=C3)N
2.2 Other Identifiers
2.2.1 UNII
NA1U919MRO
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 4-piperidinecarboxylic Acid, 4-amino-1-((2r)-6-amino-2-(((2r)-2-(((2r)-2-(((2r)-2-amino-1-oxo-3-phenylpropyl)amino)-1-oxo-3-phenylpropyl)amino)-4-methyl-1-oxopentyl)amino)-1-oxohexyl)-

2. Korsuva

3. N-((2r)-1-(((2r)-1-(((2r)-6-amino-1-(4-amino-4-carboxy-1-piperidinyl)-1-oxo-2-hexanyl)amino)-4-methyl-1-oxo-2-pentanyl)amino)-1-oxo-3-phenyl-2-propanyl)-d-phenylalaninamide

2.3.2 Depositor-Supplied Synonyms

1. 1024828-77-0

2. Cr845

3. Difelikefalin [inn]

4. Mr13a9

5. Cr-845

6. Korsuva

7. Fe202845

8. Na1u919mro

9. Fe-202845

10. Mr-13a9

11. 1024828-77-0 (free Base)

12. 1-(d-phenylalanyl-d-phenylalanyl-d-leucyl-d-lysyl)-4-aminopiperidine-4-carboxylic Acid

13. 4-piperidinecarboxylic Acid, N1-(d-phenylalanyl-d-phenylalanyl-d-leucyl-d-lysyl)-4-amino-

14. 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic Acid

15. Difelikefalin Acetate [jan]

16. Unii-na1u919mro

17. Kapruvia

18. Difelikefalin Tfa

19. Cr 845

20. Difelikefalin (cr845)

21. Difelikefalin (usan/inn)

22. Difelikefalin [usan:inn]

23. Difelikefalin [usan]

24. Seq Id No: 2

25. Difelikefalin [who-dd]

26. Gtpl9044

27. Chembl3989915

28. Schembl10316464

29. Bdbm235785

30. Dtxsid401032896

31. Bcp24752

32. Ex-a5855

33. At30197

34. Db11938

35. Bd177570

36. Hy-17609

37. Cr-845; Fe-202845

38. Cs-0014687

39. D11111

40. Us9359399, 2

41. Q21098992

42. D-phe-d-phe-d-leu-d-lys-[gamma-(4-n-piperidinyl)amino Carboxylic Acid]

43. 4-piperidinecarboylic Acid, 4-amino-1-(d-phenylalanyl-d-phenylalanyl-d-leucyl-d-lysyl)-

44. 4-amino-1-(d-phenylalanyl-d-phenylalanyl-d-leucyl-d-lysyl)piperidine-4-carboxylic Acid

45. 4-piperidinecarboxylic Acid, 4-amino-1-((2r)-6-amino-2-(((2r)-2-(((2r)-2-(((2r)-2-amino-1-oxo-3-phenylpropyl)amino)-1-oxo-3-phenylpropyl)amino)-4-methyl-1-oxopentyl)amino)-1-oxohexyl)-

46. N-((2r)-1-(((2r)-1-(((2r)-6-amino-1-(4-amino-4-carboxy-1-piperidinyl)-1-oxo-2-hexanyl)amino)-4-methyl-1-oxo-2-pentanyl)amino)-1-oxo-3-phenyl-2-propanyl)-d-phenylalaninamide

2.4 Create Date
2008-05-26
3 Chemical and Physical Properties
Molecular Weight 679.8 g/mol
Molecular Formula C36H53N7O6
XLogP3-0.6
Hydrogen Bond Donor Count7
Hydrogen Bond Acceptor Count9
Rotatable Bond Count18
Exact Mass679.40573244 g/mol
Monoisotopic Mass679.40573244 g/mol
Topological Polar Surface Area223 Ų
Heavy Atom Count49
Formal Charge0
Complexity1080
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Difelikefalin is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP; uremic pruritus) in adults undergoing hemodialysis.


FDA Label


Kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5. 1).


5 Pharmacology and Biochemistry
5.1 Pharmacology

Difelikefalin is administered to patients undergoing hemodialysis for chronic kidney disease (CKD) to prevent and treat the pruritus often associated with CKD. It is administered via bolus intravenous injection at the end of each hemodialysis treatment. As it works on opioid receptors, difelikefalin can cause dizziness, somnolence, and other CNS depressant effects that may impair mental or physical abilities - as such, patients should be advised to avoid operating dangerous machinery until the effect of difelikefalin on that patient is known.


5.2 ATC Code

V03AX


V - Various

V03 - All other therapeutic products

V03A - All other therapeutic products

V03AX - Other therapeutic products

V03AX04 - Difelikefalin


5.3 Absorption, Distribution and Excretion

Absorption

Difelikefalin is administered via bolus intravenous injection with each hemodialysis treatment - for this reason, each dose is effectively 100% bioavailable.


Route of Elimination

Following intravenous difelikefalin administration to hemodialysis patients, approximately 11% of the dose was excreted in the urine, 59% in the feces, and 20% in the dialysate.


Volume of Distribution

The mean volume of distribution of difelikefalin is approximately 238 mL/kg.


Clearance

One cycle of hemodialysis reduces difelikefalin plasma concentrations by 70-80% and no detectable drug remains after two cycles.


5.4 Metabolism/Metabolites

Difelikefalin is not metabolized to any appreciable extent and is not a substrate for cytochrome P450 enzymes.


5.5 Biological Half-Life

The half-life of difelikefalin in hemodialysis patients prior to dialysis ranges between 23 and 31 hours.


5.6 Mechanism of Action

Difelikefalin is a synthetic peptide and agonist of kappa opioid receptors (KORs), which have long been known to be involved with the itching sensation (in addition to playing some role in addiction). Endogenous KOR agonists - called dynorphins - have a neuroinhibitory effect on the itching sensation at the spinal cord level and mouse models have shown KOR agonist antipruritic activity when used to treat itching induced by different pruritogens. Although the specifics of the mechanism have yet to be elucidated, the administration of KOR agonists, like difelikefalin, in patients with uremic pruritus has proven an effective means to suppress scratching and improve their quality of life.


API SUPPLIERS

read-more
read-more

01

Neuland Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNeuland Laboratories- A dedicated 100% API provider.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Neuland

02

Aspen API

Netherlands

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAspen API. More than just an API.

Flag Netherlands
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Aspen API Comapny Banner

03

Chunghwa Chemical Synthesis & Biot...

Taiwan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Flag Taiwan
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
CCSB Company Banner

04

Omgene Life Sciences Pvt. Ltd

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Omgene Company Banner

05

ALP Pharm

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Antibody Engineering
Not Confirmed
arrow

ALP Pharm

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Antibody Engineering
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

06

Cipla

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Antibody Engineering
Not Confirmed
arrow

Cipla

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Antibody Engineering
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

07

PolyPeptide Group

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Antibody Engineering
Not Confirmed
arrow

PolyPeptide Group

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Antibody Engineering
Not Confirmed
USDMF CEP/COS JDMF arrow-down EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-more

01

Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Flag Taiwan
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 38511

Submission : 2023-06-19

Status : Active

Type : II

CCSB Company Banner

02

Antibody Engineering
Not Confirmed

03

Cipla Ltd

India

USDMF

arrow
Antibody Engineering
Not Confirmed

03

Cipla Ltd

India
arrow
Antibody Engineering
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 37712

Submission : 2023-01-25

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

read-more
read-more

01

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

Difelikefalin

Registration Number : 304MF10128

Registrant's Address : 7 rue de Boulogne 67100 Strasbourg, France

Initial Date of Registration : 2022-09-08

Latest Date of Registration : 2023-07-19

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-more

01

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Flag Taiwan
Digital Content Digital Content

DIFELIKEFALIN ACETATE

NDC Package Code : 52076-6273

Start Marketing Date : 2021-12-14

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

CCSB Company Banner

02

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

DIFELIKEFALIN

NDC Package Code : 59162-0002

Start Marketing Date : 2021-01-08

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNeuland Laboratories- A dedicated 100% API provider.

Flag India
Digital Content Digital Content

Difelikefalin

About the Company : Established in 1984, Neuland Laboratories Limited is a publicly listed company headquartered in Hyderabad, India. The company provides solutions across the entire spectrum of the p...

Established in 1984, Neuland Laboratories Limited is a publicly listed company headquartered in Hyderabad, India. The company provides solutions across the entire spectrum of the pharmaceutical industry’s chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. Neuland’s expertise is in the manufacturing of APIs and advanced intermediates from its USFDA-approved facilities. Its core competency lies in the application of powerful process chemistry to manufacturing in a regulatory-compliant environment.
Neuland

02

Aspen API

Netherlands
arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAspen API. More than just an API.

Flag Netherlands
Digital Content Digital Content

Difelikefalin

About the Company : Aspen API is the cooperative entity formed by Aspen Oss in the Netherlands and Fine Chemicals Corporation in South Africa. With quality, compliance, and teamwork at its core, Aspen...

Aspen API is the cooperative entity formed by Aspen Oss in the Netherlands and Fine Chemicals Corporation in South Africa. With quality, compliance, and teamwork at its core, Aspen API works tirelessly to deliver top-quality APIs to clients worldwide. Aspen API has a portfolio of over 58 high-quality APIs, including high potency, oncology, peptides, narcotics, analgesics, botanical extractions, and biochemicals. Aspen API places a strong emphasis on sustainability. It employs eco-friendly technologies and solvents in its chemical processes, ensuring responsible and environmentally conscious manufacturing.
Aspen API Comapny Banner

03

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Flag Taiwan
Digital Content Digital Content

Difelikefalin

About the Company : Chunghwa Chemical Synthesis & Biotech Co. Ltd. (CCSB) offers global customers cost-effective APIs with speed, supported by our well-trained staff. As the first company in Southeast...

Chunghwa Chemical Synthesis & Biotech Co. Ltd. (CCSB) offers global customers cost-effective APIs with speed, supported by our well-trained staff. As the first company in Southeast Asia to receive FDA approval for synthetic and biotech APIs, CCSB has a proven track record of commercializing Statin, Immunosuppressant, Muscle Relaxant, and ACE Inhibitor APIs, all with complete DMF or COS. For years, CCSB has partnered with leading brand and generic drug companies to develop and produce APIs and advanced intermediates, focusing on specialty APIs crafted through a sophisticated fusion of fermentation and synthesis technologies in Taiwan.
CCSB Company Banner

04

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Flag India
Digital Content Digital Content

Difelikefalin

About the Company : Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically...

Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integrated company, we focus on developing high-quality formulations based on in-house-produced actives. With GMP-certified facilities and partnerships with contract manufacturers, we excel in formulation development for injectables, lyophilized injectables, complex generics, and oral peptide delivery systems, ensuring affordable, top-quality medicines.
Omgene Company Banner

05

ALP Pharm

China
Antibody Engineering
Not Confirmed
arrow

ALP Pharm

China
arrow
Antibody Engineering
Not Confirmed

Difelikefalin

About the Company : ALP Pharm began to manufacture some APIs in the partner's facilities in 2007. Some of our APIs have been approved by EDQM and US FDA. Our professional regulatory compliance experts...

ALP Pharm began to manufacture some APIs in the partner's facilities in 2007. Some of our APIs have been approved by EDQM and US FDA. Our professional regulatory compliance experts in the USA, United Kingdom, and India have more than 10 years of Western cGMP experience. Prior to working for ALP Pharm, they have helped more than 30 pharmaceutical companies achieve ANDAs and DMFs and also helped some branded companies to pass FDA inspections for the NDA and IND. Meanwhile, they helped some European pharmaceutical companies to get licenses for finished drugs including oral solid dosages and injections, as well as COSs and EDMFs.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Korsuva (difelikefalin) is a kappa opioid receptor agonists. Its oral formulation is under development for the treatment of moderate-to-severe pruritus in adult patients with notalgia paresthetica.


Lead Product(s): Difelikefalin

Therapeutic Area: Dermatology Brand Name: Korsuva

Study Phase: Phase II/ Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 12, 2024

blank

01

Antibody Engineering
Not Confirmed
Antibody Engineering
Not Confirmed

Details : Korsuva (difelikefalin) is a kappa opioid receptor agonists. Its oral formulation is under development for the treatment of moderate-to-severe pruritus in adult patients with notalgia paresthetica.

Brand Name : Korsuva

Molecule Type : Peptide

Upfront Cash : Not Applicable

June 12, 2024

blank

Details:

CR845 (difelikefalin) is a kappa opioid receptor agonists. Its oral formulation is under clinical development for the treatment of moderate-to-severe pruritus in patients with Atopic Dermatitis.


Lead Product(s): Difelikefalin

Therapeutic Area: Dermatology Brand Name: CR845

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 18, 2023

blank

02

Antibody Engineering
Not Confirmed
Antibody Engineering
Not Confirmed

Details : CR845 (difelikefalin) is a kappa opioid receptor agonists. Its oral formulation is under clinical development for the treatment of moderate-to-severe pruritus in patients with Atopic Dermatitis.

Brand Name : CR845

Molecule Type : Peptide

Upfront Cash : Not Applicable

December 18, 2023

blank

Details:

Cara intends to use the proceeds from the agreement to support the ongoing clinical development of its oral CR845 (difelikefalin) pipeline, including late-stage programs for pruritus associated with atopic dermatitis, advanced chronic kidney disease, and notalgia paresthetica.


Lead Product(s): Difelikefalin

Therapeutic Area: Dermatology Brand Name: CR845

Study Phase: Phase IIProduct Type: Peptide

Sponsor: HealthCare Royalty

Deal Size: $40.0 million Upfront Cash: Undisclosed

Deal Type: Financing November 02, 2023

blank

03

Antibody Engineering
Not Confirmed
Antibody Engineering
Not Confirmed

Details : Cara intends to use the proceeds from the agreement to support the ongoing clinical development of its oral CR845 (difelikefalin) pipeline, including late-stage programs for pruritus associated with atopic dermatitis, advanced chronic kidney disease, and...

Brand Name : CR845

Molecule Type : Peptide

Upfront Cash : Undisclosed

November 02, 2023

blank

Details:

Korsuva (difelikefalin) injection is a kappa opioid receptor agonist indicated for the treatment of moderate-to-severe pruritus in hemodialysis patients.


Lead Product(s): Difelikefalin

Therapeutic Area: Dermatology Brand Name: Korsuva

Study Phase: ApprovedProduct Type: Peptide

Sponsor: Maruishi Pharmaceutical

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 25, 2023

blank

04

Antibody Engineering
Not Confirmed
Antibody Engineering
Not Confirmed

Details : Korsuva (difelikefalin) injection is a kappa opioid receptor agonist indicated for the treatment of moderate-to-severe pruritus in hemodialysis patients.

Brand Name : Korsuva

Molecule Type : Peptide

Upfront Cash : Not Applicable

September 25, 2023

blank

Details:

Kapruvia® (difelikefalin) is a selective kappa opioid receptor agonist with low central nervous system penetration. It is recommended by NICE for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.


Lead Product(s): Difelikefalin

Therapeutic Area: Nephrology Brand Name: Kapruvia

Study Phase: ApprovedProduct Type: Peptide

Sponsor: CARA Therapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2023

blank

05

CSL Vifor

Switzerland
arrow
Antibody Engineering
Not Confirmed

CSL Vifor

Switzerland
arrow
Antibody Engineering
Not Confirmed

Details : Kapruvia® (difelikefalin) is a selective kappa opioid receptor agonist with low central nervous system penetration. It is recommended by NICE for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.

Brand Name : Kapruvia

Molecule Type : Peptide

Upfront Cash : Not Applicable

May 18, 2023

blank

Details:

CR845 (difelikefalin) is an oral agonist of kappa opioid receptors (KORs) It is being developed for the treatment of pruritus secondary to chronic kidney disease and notalgia paresthetica.


Lead Product(s): Difelikefalin

Therapeutic Area: Neurology Brand Name: CR845

Study Phase: Phase IIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 08, 2023

blank

06

Antibody Engineering
Not Confirmed
Antibody Engineering
Not Confirmed

Details : CR845 (difelikefalin) is an oral agonist of kappa opioid receptors (KORs) It is being developed for the treatment of pruritus secondary to chronic kidney disease and notalgia paresthetica.

Brand Name : CR845

Molecule Type : Peptide

Upfront Cash : Not Applicable

February 08, 2023

blank

Details:

The milestone payment is related to continued clinical progress of Oral KORSUVA (difelikefalin), which is currently the subject of four separate clinical programs for pruritus in patients with hepatic impairment due to primary biliary cholangitis.


Lead Product(s): Difelikefalin

Therapeutic Area: Dermatology Brand Name: Korsuva

Study Phase: Phase IIProduct Type: Peptide

Sponsor: CARA Therapeutics

Deal Size: $46.0 million Upfront Cash: $8.0 million

Deal Type: Licensing Agreement October 10, 2022

blank

07

Antibody Engineering
Not Confirmed
Antibody Engineering
Not Confirmed

Details : The milestone payment is related to continued clinical progress of Oral KORSUVA (difelikefalin), which is currently the subject of four separate clinical programs for pruritus in patients with hepatic impairment due to primary biliary cholangitis.

Brand Name : Korsuva

Molecule Type : Peptide

Upfront Cash : $8.0 million

October 10, 2022

blank

Details:

The primary efficacy endpoint of change from baseline in the weekly mean of the daily 24-hour Worst Itch-Numeric Rating Scale (WI-NRS) score at Week 8 was achieved for Korsuva (difelikefalin) vs. -2.4 placebo, p=0.001.


Lead Product(s): Difelikefalin

Therapeutic Area: Neurology Brand Name: Korsuva

Study Phase: Phase IIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 08, 2022

blank

08

Antibody Engineering
Not Confirmed
Antibody Engineering
Not Confirmed

Details : The primary efficacy endpoint of change from baseline in the weekly mean of the daily 24-hour Worst Itch-Numeric Rating Scale (WI-NRS) score at Week 8 was achieved for Korsuva (difelikefalin) vs. -2.4 placebo, p=0.001.

Brand Name : Korsuva

Molecule Type : Peptide

Upfront Cash : Not Applicable

September 08, 2022

blank

Details:

KOMFORT Phase 2 clinical trial evaluating oral Korsuva (difelikefalin) for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica will be presented during a late-breaking news session.


Lead Product(s): Difelikefalin

Therapeutic Area: Dermatology Brand Name: Korsuva

Study Phase: Phase IIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 22, 2022

blank

09

Antibody Engineering
Not Confirmed
Antibody Engineering
Not Confirmed

Details : KOMFORT Phase 2 clinical trial evaluating oral Korsuva (difelikefalin) for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica will be presented during a late-breaking news session.

Brand Name : Korsuva

Molecule Type : Peptide

Upfront Cash : Not Applicable

August 22, 2022

blank

Details:

Kapruvia® (difelikefalin) will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients.


Lead Product(s): Difelikefalin

Therapeutic Area: Dermatology Brand Name: Kapruvia

Study Phase: ApprovedProduct Type: Peptide

Sponsor: CARA Therapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 19, 2022

blank

10

CSL Vifor

Switzerland
arrow
Antibody Engineering
Not Confirmed

CSL Vifor

Switzerland
arrow
Antibody Engineering
Not Confirmed

Details : Kapruvia® (difelikefalin) will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients.

Brand Name : Kapruvia

Molecule Type : Peptide

Upfront Cash : Not Applicable

August 19, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

DIFELIKEFALIN ACETATE

Brand Name : KORSUVA

Dosage Form : SOLUTION;INTRAVENOUS

Dosage Strength : EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML)

Packaging :

Approval Date : 2021-08-23

Application Number : 214916

Regulatory Info : RX

Registration Country : USA

blank

02

CSL Vifor

Switzerland
Antibody Engineering
Not Confirmed
arrow

CSL Vifor

Switzerland
arrow
Antibody Engineering
Not Confirmed

Difelikefalinum

Brand Name : Kapruvia

Dosage Form : Inj L?s

Dosage Strength : 0.05mg/ml

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

03

Seqirus

Australia
Antibody Engineering
Not Confirmed
arrow

Seqirus

Australia
arrow
Antibody Engineering
Not Confirmed

difelikefalin

Brand Name : Korsuva

Dosage Form :

Dosage Strength :

Packaging : 12

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

04

Seqirus

Australia
Antibody Engineering
Not Confirmed
arrow

Seqirus

Australia
arrow
Antibody Engineering
Not Confirmed

difelikefalin

Brand Name : Korsuva

Dosage Form :

Dosage Strength :

Packaging : 12

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

05

Seqirus

Australia
Antibody Engineering
Not Confirmed
arrow

Seqirus

Australia
arrow
Antibody Engineering
Not Confirmed

difelikefalin

Brand Name : Korsuva

Dosage Form :

Dosage Strength :

Packaging : 12

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

06

Seqirus

Australia
Antibody Engineering
Not Confirmed
arrow

Seqirus

Australia
arrow
Antibody Engineering
Not Confirmed

difelikefalin

Brand Name : Korsuva

Dosage Form :

Dosage Strength :

Packaging : 12

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

CARA THERAP

India
Antibody Engineering
Not Confirmed
arrow

CARA THERAP

India
arrow
Antibody Engineering
Not Confirmed

DIFELIKEFALIN ACETATE

Brand Name : KORSUVA

Dosage Form : SOLUTION;INTRAVENOUS

Dosage Strength : EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML)

Approval Date : 2021-08-23

Application Number : 214916

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

Difelikefalinum

Brand Name : Kapruvia

Dosage Form : Inj L?s

Dosage Strength : 0.05mg/ml

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Australia

read-more
read-more

01

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

difelikefalin

Brand Name : Korsuva

Dosage Form :

Dosage Strength :

Packaging : 12

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

02

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

difelikefalin

Brand Name : Korsuva

Dosage Form :

Dosage Strength :

Packaging : 12

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

03

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

difelikefalin

Brand Name : Korsuva

Dosage Form :

Dosage Strength :

Packaging : 12

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

04

Antibody Engineering
Not Confirmed
arrow
arrow
Antibody Engineering
Not Confirmed

difelikefalin

Brand Name : Korsuva

Dosage Form :

Dosage Strength :

Packaging : 12

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
Antibody Engineering
Not Confirmed

CARA THERAP

India
arrow
Antibody Engineering
Not Confirmed

DIFELIKEFALIN ACETATE

US Patent Number : 10138270

Drug Substance Claim :

Drug Product Claim :

Application Number : 214916

Patent Use Code : U-3204

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-11-12

blank

02

arrow
Antibody Engineering
Not Confirmed

CARA THERAP

India
arrow
Antibody Engineering
Not Confirmed

DIFELIKEFALIN ACETATE

US Patent Number : 8217007

Drug Substance Claim :

Drug Product Claim :

Application Number : 214916

Patent Use Code : U-3204

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-11-12

blank

03

arrow
Antibody Engineering
Not Confirmed

CARA THERAP

India
arrow
Antibody Engineering
Not Confirmed

DIFELIKEFALIN ACETATE

US Patent Number : 8236766

Drug Substance Claim :

Drug Product Claim :

Application Number : 214916

Patent Use Code : U-3204

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-11-12

blank

04

arrow
Antibody Engineering
Not Confirmed

CARA THERAP

India
arrow
Antibody Engineering
Not Confirmed

DIFELIKEFALIN ACETATE

US Patent Number : 8486894

Drug Substance Claim :

Drug Product Claim :

Application Number : 214916

Patent Use Code : U-3204

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-11-12

blank

05

arrow
Antibody Engineering
Not Confirmed

CARA THERAP

India
arrow
Antibody Engineering
Not Confirmed

DIFELIKEFALIN ACETATE

US Patent Number : 8536131

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 214916

Patent Use Code : U-3204

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-11-12

blank

06

arrow
Antibody Engineering
Not Confirmed

CARA THERAP

India
arrow
Antibody Engineering
Not Confirmed

DIFELIKEFALIN ACETATE

US Patent Number : 9334305

Drug Substance Claim :

Drug Product Claim :

Application Number : 214916

Patent Use Code : U-3204

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-11-12

blank

07

arrow
Antibody Engineering
Not Confirmed

CARA THERAP

India
arrow
Antibody Engineering
Not Confirmed

DIFELIKEFALIN ACETATE

US Patent Number : 10793596

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 214916

Patent Use Code : U-3204

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-11-12

blank

08

arrow
Antibody Engineering
Not Confirmed

CARA THERAP

India
arrow
Antibody Engineering
Not Confirmed

DIFELIKEFALIN ACETATE

US Patent Number : 9359399

Drug Substance Claim :

Drug Product Claim :

Application Number : 214916

Patent Use Code : U-3204

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-11-12

blank

09

arrow
Antibody Engineering
Not Confirmed

CARA THERAP

India
arrow
Antibody Engineering
Not Confirmed

DIFELIKEFALIN ACETATE

US Patent Number : 7713937

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 214916

Patent Use Code : U-3204

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-11-12

blank

10

arrow
Antibody Engineering
Not Confirmed

CARA THERAP

India
arrow
Antibody Engineering
Not Confirmed

DIFELIKEFALIN ACETATE

US Patent Number : 10017536

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 214916

Patent Use Code : U-3204

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-11-12

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty